title: New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.
abstract: OBJECTIVE
  Neurological complications such as chemotherapy-induced peripheral neuropathy (CIPN) and neuropathic pain are frequent side effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention, and treatment of these neurological complications be implemented.
  
  
  METHODS
  A consideration was undertaken of the current options regarding protective and treatment interventions for patients undergoing chemotherapy with neurotoxic chemotherapy agent or experience with CIPN. Current knowledge on the mechanism of action has also been identified. The following databases PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, CINAHL, CNKI, and Google Scholar were searched for relevant article retrieval.
  
  
  RESULTS
  A range of pharmaceutical, nutraceutical, and herbal medicine treatments were identified that either showed efficacy or had some evidence of efficacy. Duloxetine was the most effective pharmaceutical agent for the treatment of CIPN. Vitamin E demonstrated potential for the prevention of cisplatin-IPN. Intravenous glutathione for oxaliplatin, Vitamin B6 for both oxaliplatin and cisplatin, and omega 3 fatty acids for paclitaxel have shown protection for CIPN. Acetyl-L-carnitine may provide some relief as a treatment option. Acupuncture may be of benefit for some patients and Gosha-jinki-gan may be of benefit for protection from adverse effects of oxaliplatin induced peripheral neuropathy.
  
  
  CONCLUSIONS
  Clinicians and researchers acknowledge that there are numerous challenges involved in understanding, preventing, and treating peripheral neuropathy caused by chemotherapeutic agents. New insights into mechanisms of action from chemotherapy agents may facilitate the development of novel preventative and treatment options, thereby enabling medical staff to better support patients by reducing this debilitating side effect.
authors.affiliation: Mater Private Breast Cancer Centre, Mater Hospital, Brisbane, Australia; Office of Research, Endeavour College of Natural Health, University of Technology, Brisbane, Australia.
authors.forename: Janet
authors.initials: J
authors.lastname: Schloss
authors.affiliation: Mater Private Breast Cancer Centre, Mater Hospital, Brisbane, Australia; Medical Oncology Group of Australia, Clinical Oncology Society of Australia, Queensland Clinical Oncology Group, Brisbane, Australia.
authors.forename: Maree
authors.initials: M
authors.lastname: Colosimo
authors.affiliation: Sydney Medical School, University of Sydney, Sydney 2006, Sydney, Australia; Medlab Clinical, Sydney, Australia.
authors.forename: Luis
authors.initials: L
authors.lastname: Vitetta
keywords: Bortezomib; chemotherapy-induced peripheral neuropathy; cisplatin; management; neuropathic pain; prevention; taxane; treatment; vincristine